Search

Your search keyword '"Devito C."' showing total 92 results

Search Constraints

Start Over You searched for: Author "Devito C." Remove constraint Author: "Devito C."
92 results on '"Devito C."'

Search Results

7. Seroreactivity to HIV-1 V3 Subtypes A to H Peptides of Argentinian HIV-Positive Sera

10. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity

11. High zonal harmonics of rapidly rotating planets

15. Using the SF-36 physical function subscale to screen for falls-risk in a clinically defined sample of at-risk elders

16. HTLV-I/II Survey On Hemodialysis Patients In Buenos Aires

22. The incidence of fall injury events among the elderly in a defined population.

26. Use of Veterans Affairs medical care by enrollees in Medicare HMOs.

27. Differential Immune Response Patterns Induced by Anionic and Cationic Lipid Adjuvants in Intranasal Anti-Influenza Immunization.

28. Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein.

29. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy.

30. Long-Lasting Mucosal and Systemic Immunity against Influenza A Virus Is Significantly Prolonged and Protective by Nasal Whole Influenza Immunization with Mucosal Adjuvant N3 and DNA-Plasmid Expressing Flagellin in Aging In- and Outbred Mice.

31. Human IgM monoclonal antibodies block HIV-transmission to immune cells in cervico-vaginal tissues and across polarized epithelial cells in vitro.

32. Targeting cancer stem-like cells as an approach to defeating cellular heterogeneity in Ewing sarcoma.

33. DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant.

34. Antiretroviral therapy does not induce HIV type 1-specific neutralizing activity against autologous HIV type 1 isolates.

35. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations.

36. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.

37. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41.

38. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects.

39. Oppositional defiant disorder with onset in preschool years: longitudinal stability and pathways to other disorders.

40. Attachment, parenting, and marital dissatisfaction as predictors of disruptive behavior in preschoolers.

41. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells.

42. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate.

43. Medicare HMO disenrollment and selective use of medical care: osteoarthritis-related joint replacement.

44. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.

45. Racial and income differences in use of the hospice benefit between the medicare managed care and medicare fee-for-service.

46. Do Medicare HMOs and Medicare FFS differ in their use of the Medicare hospice benefit?

47. Home environmental hazards and the risk of fall injury events among community-dwelling older persons. Study to Assess Falls Among the Elderly (SAFE) Group.

48. Medicare HMOs: who joins and who leaves?

49. [Evaluation of indirect immunofluorescence as a supplementary test for the diagnosis of HIV-1 infection].

50. The Medicare-HMO revolving door--the healthy go in and the sick go out.

Catalog

Books, media, physical & digital resources